Pacific Biosciences of California (NASDAQ: PACB ) achieves a development milestone under its agreement with Roche ( OTCQX: RHHBY ) triggering a $10M milestone payment. The companies signed a Development, Commercialization and License Agreement on September
diagnostics is still a relatively new opportunity in the clinical diagnostics space - about $4 billion/year if Roche 's (OTCQX: RHHBY ) estimates of its market share are accurate. It remains a good growth opportunity, though, as molecular diagnostic technologies
By Stephen Simpson, CFA : Roche ( OTCQX: RHHBY ) does a lot of things well. It is one of the largest players in oncology and markets three of the top ten best-selling drugs
By DoctoRx : Background : On August 8, I did my first and only article on Regeneron (NASDAQ: REGN ), titled The Case That Regeneron May Be Significantly Undervalued . This company has a rapidly-growing franchise for retinal problems and a large partnership with the French major pharma company ...
By EnhydrisPECorp : Prothena Corporation plc (NASDAQ: PRTA ) is a little-known Irish biopharma developing novel treatments for a host of rogue protein-based diseases that reap absolute havoc within our bodies. Some examples of these killers include Alzheimers, Parkinsons, and Amyloid Light-chain ...
Roche's ( OTCQX: RHHBY +0.6% ) $8.3B acquisition of InterMune ( ITMN +35.7% ) fuels an inflow of money into the biotech sector today. The iShares NASDAQ Biotech Index ETF ( IBB +2.2% ) is up on average volume. ETFs: BIB , BIS Post your comment!
adults in October 2013. Related tickers: ( PFE +0.1% ) ( MRK +0.9% ) ( OTCPK:BAYZF ) ( OTCPK:BAYRY +1.2% ) ( OTCQX: RHHBY +0.6% ) ( TEVA -0.5% ) ( MYL +0.8% ) ( PRGO -0.1% ) ( GSK +0.8% ) Post your comment!
Shares of Chugai Pharmaceutical Co. dropped over 9% on the Tokyo exchange after Roche ( OTCQX: RHHBY ) decided to spend its money on InterMune (NASDAQ: ITMN ) instead. According to Chugai, "it is in no way in the process of
Roche ( OTCQX: RHHBY , OTCPK:RHHBF ) will pay $74/share for InterMune (NASDAQ: ITMN ), a 38% premium to its Friday close and 63% higher than
By Stephen Simpson, CFA : Oncology biotech Seattle Genetics (NASDAQ: SGEN ) has had a bit of an interesting ride since I reviewed the company's prospects and valuation back in December. The shares moved up about 40% through February of this year on optimism for the company's deep portfolio of ...